Ionis' Tryngolza wins CHMP backing for severe hypertriglyceridemia
Bitget2026/10/16 10:45- EMA's CHMP recommended expanding approval of Ionis Pharmaceuticals' TRYNGOLZA to adults with severe hypertriglyceridemia with fasting triglycerides ≥880 mg/dL.
- A final European Commission decision is expected in the fourth quarter of 2026, ahead of the previously anticipated timeline.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nomura: Bond short squeeze and AI selloff trigger cross-asset 'reverse dispersion' rotation, with capital flowing into value stocks and small-cap stocks
Nomura Securities analyst McElligott believes that bond tightening and turmoil in the field of artificial intelligence will lead to a market reversal.
AI Is Splitting Software Into Winners and Losers, Citi’s Tyler Radke Says
KOSPI Jumps 3.54%, Nikkei Gains 1.43%, But How Is Oil Driving the Rebound?
Wedbush Bullish on AMD (AMD.US) Before Earnings: Server CPUs Take the Lead, 2027 Guidance Awaits Validation
AMD will announce its Q3 FY2026 results on November 3. Wedbush analyst Matt Bryson stated in the latest outlook that the actual figures for this quarter may not be the biggest variable; rather, the strength of server CPU sales will determine the short-term upside potential.
Crypto prices
More
